Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing is everything: new study aims to find the best window to treat dangerous blood clots in the lungs

NCT ID NCT07436702

Knowledge-focused Sponsor: Azienda ULSS 8 Berica Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is observing 500 adults with severe pulmonary embolism (a dangerous blood clot in the lungs) to see if the timing of clot-busting treatments affects survival and complications. Researchers want to find the optimal time window to start treatment, similar to how heart attacks and strokes are treated. The goal is to improve outcomes by understanding when treatment is most effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a confirmed diagnosis of high-risk or intermediate-high-risk pulmonary embolism according to the 2019 European Society of Cardiology guidelines.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Patients with a diagnosis of intermediate-high or high pulmonary embolism confirmed by computed tomography pulmonary angiography (CTPA), pulmonary angiography, or echocardiography (evidence of a floating thrombus in the right atrium or right ventricle, or proximal visualization of thrombus in the pulmonary artery). * Classified as high-risk or intermediate-high-risk according to the 2019 European Society of Cardiology guidelines. * Provision of informed consent for the processing of personal data. Exclusion Criteria: * Age \< 18 years * Patients in whom a diagnosis of acute high-risk or intermediate-high-risk pulmonary embolism has been excluded. * Inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary embolism (diagnosis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary embolism (diagnosis) Pulmonary embolism acute

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS Policlinico San Matteo

    RECRUITING

    Pavia, Pavia, 27100, Italy

  • UO Unità di Cure Intensive Cardiologiche e Cardiologia 1, Ospedale Niguarda, Milano

    RECRUITING

    Milan, Milano, 20162, Italy

  • UO di Cardiologia 1, Azienda Ospedaliero Universitaria Pisana, Pisa, Italia

    RECRUITING

    Pisa, Pisa, 56126, Italy

  • UO di Cardiologia, Azienda Ospedaliera Ordine Mauriziano di Torino

    RECRUITING

    Torino, Torino, 10128, Italy

  • UO di Sezione di Medicina Interna e Cardiovascolare, Ospedale Santa Maria della Misericordia, Perugia, Italia

    RECRUITING

    Perugia, Perugia, 06129, Italy

  • UOC di Cardiologia, Ospedali Riuniti Padova Sud, Monselice, Italia

    RECRUITING

    Monselice, Padova, 35043, Italy

  • UOC di Cardiologia, Ospedali dell'Ovest Vicentino, Arzignano, IItalia

    RECRUITING

    Arzignano, Vicenza, 36071, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.